245 related articles for article (PubMed ID: 34249417)
1. A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.
Lawal B; Lo WC; Mokgautsi N; Sumitra MR; Khedkar H; Wu AT; Huang HS
Am J Cancer Res; 2021; 11(6):2590-2617. PubMed ID: 34249417
[TBL] [Abstract][Full Text] [Related]
2. Erratum: A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers.
Lawal B; Lo WC; Mokgautsi N; Sumitra MR; Khedkar H; Wu AT; Huang HS
Am J Cancer Res; 2021; 11(11):5761. PubMed ID: 34873494
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways.
Yang XL; Lin FJ; Guo YJ; Shao ZM; Ou ZL
Onco Targets Ther; 2014; 7():1033-42. PubMed ID: 24966685
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
5. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
11. mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.
Lawal B; Lee CY; Mokgautsi N; Sumitra MR; Khedkar H; Wu ATH; Huang HS
Front Oncol; 2021; 11():656738. PubMed ID: 33842373
[TBL] [Abstract][Full Text] [Related]
12. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
14. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.
Rosenberg L; Yoon CH; Sharma G; Bertagnolli MM; Cho NL
Carcinogenesis; 2018 May; 39(5):681-688. PubMed ID: 29538717
[TBL] [Abstract][Full Text] [Related]
16. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
18. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-Kinase/Akt and MEK/ERK Signaling Pathways Facilitate Sapovirus Trafficking and Late Endosomal Acidification for Viral Uncoating in LLC-PK Cells.
Soliman M; Kim DS; Park JG; Kim JY; Alfajaro MM; Baek YB; Cho EH; Park CH; Kang MI; Park SI; Cho KO
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
